白蛋白紫杉醇治疗复发性广泛期小细胞肺癌的疗效观察

目的 探讨白蛋白紫杉醇治疗复发广泛期小细胞肺癌的临床疗效和不良反应.方法 2017 年6月至2019 年6 月期间患者24例，行白蛋白紫杉醇130 mg/m （d1，8，15）单药静脉化疗，每4周为1个疗程，每2个疗程评价疗效.结果 24例患者中，部分缓解（PR）8例（33.3%），疾病稳定（SD）7例（29.2%），疾病进展（PD）9 例（37.5%）；客观缓解率（ORR）33.3%，疾病控制率（DCR）62.5%；中位无进展生存时间（mPFS）3.6个月，中位总生存时间（mOS）8.3个月.主要不良反应为，中性粒细胞减少(37.5% )，脱发(29.2% )，外周神经毒性(16.7% ).结论 白蛋白紫杉醇治疗复发难治广泛期小细胞肺癌有一定疗效，不良反应可以耐受，值得进一步开展大样本研究.

Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer

The clinical efficacy and adverse effects of nab-paclitaxel in patients with relapsed extensive-stage small-cell lung cancer have been researched. Clinical data of 24 relapsed extensive-stage small-cell lung cancer patients who received nab-paclitaxel as single agent between June 2017 and June 2019 were collected, and the curative and adverse effects of the compound were evaluated. All patients were treated with 130 mg/m nab-paclitaxel on days 1, 8, and 15. The cycle was repeated every 4 weeks. Clinical efficacy was evaluated every two cycles. Results showed that among 24 patients, including 18 males and 6 females, the median age being 65 years （range 45～77 years）, 8 patients (33.3%) achieved partial response, 7 patients (29.2%) had a stable disease, and 9 patients (37.5%) had progressive disease. The objective response rate was 33.3%, and the disease control rate was 62.5%. The median progression-free survival was 3.6 months and median overall survival was 8.3 months. The major adverse reactions included neutropenia (37.5% ), alopecia (29.2% ), and sensory neuropathy (16.7% ). It can be concluded that nab-paclitaxel has curative effects, and its adverse effects are tolerable. Further research with a larger sample size is warranted to confirm these results.